Guizhou Xinbang Pharmaceutical Co., Ltd (China)

This is a pharmaceutical company based on the integration of planting, drug development, production and sales. The main product category includes heart and brain blood vessels and digestive. The company has 44 varieties of the product with code number approved by SFDA, including 24 varieties of national basic medical insurance, the state four varieties at competitive prices, 4 species protective medicine, 2 exclusive varieties. Liuwei Anxiao capsule which is currently the first multi-center clinical study of all-natural gastrointestinal motility, Yixin capsule has maintained a 100% market share; Ginkgo biloba for the national armed forces within the hospital system exclusive successful varieties. Currently, the company has 11 varieties in the research, of which 43 million investment in research and development with independent intellectual property rights of New Drug for ginsenoside-Rd Injection has completed Phase Ⅲ clinical summary; mental health drugs medicine six capsules, eight categories of Chinese medicine Breviscapine pills clinical trials have been completed, pending the production of approval.